Axial Spondyloarthritis Treatment Market to be dominated by Growing Prevalence of Axial Spondyloarthritis through 2027
Rise in research and
development activities coupled with increasing public awareness of the disease
to drive the axial spondyloarthritis treatment market in the forecast period,
2023-2027.
According to TechSci Research report, “Axial
Spondyloarthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2017-2027”, the global axial spondyloarthritis treatment market
is anticipated to grow at a significant rate in the forecast period, 2023-2027.
The increase in incidences of axial spondyloarthritis, and rising technological
advancements are the primary factors driving the demand for the global axial
spondyloarthritis treatment market. Growing public awareness of the disease,
rise in geriatric population, large number of clinical trials, and significant
investment in research and development are expected to influence the market
demand. Also, emphasis of several authorities on improving existing healthcare
infrastructure is also a key factor for increasing the growth of the axial
spondyloarthritis treatment market, globally.
However, the high cost associated with biologics
used to treat axial spondyloarthritis (axSpA), and adverse effects from the
treatment regime may hamper the growth of the global axial spondyloarthritis
treatment market.
Browse over XX market
data Figures spread through 110 Pages and an in-depth TOC on "Axial Spondyloarthritis Treatment Market"
The global axial
spondyloarthritis treatment market is segmented into therapy, indication, end
user and company.
Based on therapy, the market
is divided into anti-tumor necrosis factor (TNF) therapy, anti-interleukin (IL)
therapy, and anti-janus kinase (JAK) therapy. The anti-tumor necrosis factor
(TNF) therapy segment is expected to hold the largest market share. This is
attributed to the significant innovations in anti-tumor necrosis factor
therapies.
Based on indication, the
market is divided into ankylosing spondylitis and non-radiographic axial
spondyloarthritis treatment. The ankylosing spondylitis segment is expected to
hold the largest market share. This is attributed to the increasing number of patients
suffering from ankylosing spondylitis, greater number of product approvals, and
growing world population.
Based on end user, the
market is divided into hospitals & clinics, academic & research
institutions, and others The academic & research institutions segment is
anticipated to grow during the forecast period. This is attributed to the
investments by governments for R&D activities, and growing research and
development activities to treat the disease.
Major companies operating
in global axial spondyloarthritis treatment market are:
- Novartis International, AG
- Eli Lilly and Company
- Johnson & Johnson
- UCB S.A.
- Pfizer, Inc.
- Kyowa Kirin Co., Ltd.
- Merck & Co., Inc.
- AbbVie Inc
- Bristol-Myers Squibb Company
- FunPep Co., Ltd.
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
“North America region dominates the
market in 2021 and is expected to maintain its dominance in the coming years
due to the increased research and development activities. The strongly
established research and healthcare infrastructure, the higher percentage of
total income spent on healthcare, several increasing developmental strategies, rising
awareness among population, favorable reimbursement, and heavy investments by
government in the region is another key factor. Also, owing to numerous biopharmaceutical companies in the region are expected to propel the
global axial spondyloarthritis treatment market growth till 2027” said Mr.
Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Axial Spondyloarthritis Treatment
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
2017-2027 Segmented By Therapy (Anti-Tumor Necrosis Factor (TNF) Therapy,
Anti-Interleukin (IL) Therapy, Anti-Janus Kinase (JAK) Therapy), By Indication
(Ankylosing Spondylitis v/s Non-radiographic Axial Spondyloarthritis
Treatment), By End User (Hospitals & Clinics, Academic & Research
Institutions, Others), By Company, and By Region”, has evaluated the future growth
potential of global axial spondyloarthritis treatment market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in global axial spondyloarthritis treatment market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com